Magid Abou-Gharbia, Ph.D., FRSC is a founder of the Moulder Center for Drug Discovery Research (MCDDR) at Temple School of Pharmacy and a Laura H. Carnell Professor of Medicinal Chemistry.. He was the directore of the Moulder Center's for 12 years. During his tenure as director, the Moulder Center pariticpate in grant funded program funded by the NIH, DOD, and several private foundations, In addition, a robost collection of intellectual property was developed and used to support the formation of three spinout biotechnology companies focused on commerciallization of technology developed at Temple Univeresity School of Pharmacy. He stepped down as Director on July 1st, 2020 and continues to be an active member of the Moulder Center's research team.
Prior to joining Temple University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was senior Vice President and Head of Chemical and Screening Sciences. As Senior Vice President & Head of Chemical & Screening Sciences at Wyeth, he was responsible for overseeing and directing Wyeth chemistry and screening research efforts of 500 scientists at four US research facilities and 150 chemists in Hyderabad, India in support of drug discovery in Neuroscience, Inflammation, Women's Health/Bone, Oncology and Cardio-vascular/Metabolic Diseases therapeutic areas.
Education: BS in Pharmacy and Pharmaceutical Sciences (1971), MS in Medicinal Chemistry (1974) from the School of Pharmacy, Cairo University, and Ph.D. (1979) from the University of Pennsylvania working with Professor Madeleine Joullie, followed by a two-year NIH Postdoctoral fellowship at Temple University Medical School and the department of chemistry.
Pharma R&D Achievements: Over the years Dr. Abou-Gharbia's group research efforts at Wyeth led to the discovery of ten marketed drugs and many compounds currently under clinical evaluation. List include: the first-in-class antidepressants Effexor™ (Venlafaxine®) and Pristiq™ (Desvenlafaxine ®); the anticancer agent Mylotarg™ (Gemtuzumab ozogamicin®); an anticancer rapamycin derivative, Torisel™ (temsirolimus®); a short-acting hypnotic Sonata™ (Zaleplon®), a broad spectrum antibiotic Tygacil™ (Tigecycline®), the anticancer kinase inhibitor Bosulif™ (Bosutinib®), a non-steroidal treatment for postmenopausal osteoporosis Viviant™ (Bazedoxifene®), the tyrosine kinase inhibitor and anticancer agent,Neratinib (Nerlynx®), and the an analgesic agent Dezocine (Dalgan®)
Research Interests: Manipulation of synthetic approaches in the design and synthesis of biologically active agents. Methodologies included: 1, 3-dipolar cycloaddition reactions, Claisen's rearrangement, Diels-Alder reactions, chemistry of ketenes, sulfilimines, synthesis of substituted steroids. Use of receptor homology, bioisoteric replacement strategies, rational and structure-based drug design approaches Utilizing natural products as a unique resource for discovering innovation therapeutics. Applying enabling technology platforms to evaluate drug-like properties of all discovered molecules to ensure clinical effectiveness of drug candidates. Design of chemical probes in support of translation medicine.
Scientific Contributions include over 340 invited lectures, presentations and publications; inventor on 125 US patents and over 350 patents worldwide. In addition, his efforts supported the formation of three spin-out biotechnology companies.
Awards and Honors include: ACS Heroes of Chemistry Award for the discovery of Effexor (2014); PA BIO Innovation Award Philadelphia Educator and Researcher of the Year (2014); Grand Hamadan Award in Drug Discovery (2014); Laura H. Carnell Professor (2013); ACS Henry Whalen Jr. Award in Business Development (2011); ACS Fellow (2010); Induction to ACS Medicinal Chemistry Hall of Fame (2008); Science & Technology Medal, R&D Council of New Jersey (2008); Heroes of Chemistry Award for the Discovery of Torisel (2008); Alfred Burger Award in Medicinal Chemistry (2008); Science and Technology Medal from the R&D Council of New Jersey (2008); selected among the Top 10 Scientists in New Jersey by New Jersey Business Magazine (2008); American Institute of Chemists (AIC) Chemistry Pioneer Award (2007); Fellow of the Royal Society of Chemistry (FRSC 2006); Researcher of the Year (2006) from Health Care Institute of NJ (HINJ); "Trailblazer Award" Minority in Research Science Award from Science Spectrum (2006); “Script Award” Best R&D Team–Wyeth Research & Development Executive Team (RADEX)(2006); “Script Award” Best Discovery Management Team–Wyeth Discovery Executive Committee (2005), Induction into the New Jersey Inventors Hall of Fame (2004); The Procter Medal (2003); ACS Earle B. Barnes Award (2001); Philadelphia Organic Chemists Club (POCC) Award (2001); Egyptian Pharmaceutical Society Drug Discovery Award (2000); Named as one of the most Prolific Inventors of the Decade by US Patent & Trade Mark (1998); ACS-Philadelphia Section Award (1997); Wyeth-Ayerst Exceptional Achievement Award (1992); and others.
Scientific and Professional Activities includes membership in the Society for Neuroscience, the American Chemical Society, the American Chemical Society Corporate Association, the New York Academy of Sciences, the Philadelphia Organic Chemists Club, Phi Lambda Upsilon, Sigma Xi, ACS Award Committee, the American Association of Colleges of Pharmacy, and the American Association of Pharmaceutical Scientists. Dr. Abou-Gharbia is also a Fellow of both the American Chemical Society and the Royal Society of Chemistry. He has also served on the editorial boards of Drugs of the Future, Drug Review and Perspectives, MedChem Letters, European Journal of Medicinal Chemistry, Synthesis, Journal of Pharmaceutical Sciences, Current CNS Patents, Journal of Organic Chemistry. In addition, he is a member of the board of visitors of Temple University’s College of Science and Technology and is a member of the scientific advisory boards of the University of Pennsylvania’s Department of Chemistry and Egypt’s Misr University for Science and Technology. Finally, he has also served as a scientific advisor and consultant for multiple major pharmaceutical and biotechnology companies.
Leadership and Mentoring: Throughout the course of his career, Dr. Abou-Gharbia has worked tirelessly with organizations across the globe in an effort to establish and implement modern paradigms for drug discovery and to promote biomedical research. His efforts were instrumental in the formation of the Moulder Center for Drug Discovery Research, a unique fully integrated drug discovery research center within Temple University's School of Pharmacy. Focused on the education and career development of the next generation of drug discovery scientists, the Moulder Center provides a hands-on experiential education in modern methods of drug discovery and development. Faculty, students, and staff scientists work together to foster both the next generation of research and cutting edge drug research through collaboration with a global network of top in class academic, public, and private institutions.
Among his recent contributions in the Middle East are the establishment of Qatar Biomedical Research Institute (QBRI), instituting medicinal chemistry and drug discovery research at four major educational institutions in the region: the University of Sharja's School of Pharmacy in the UAE, the Misr University for Science and Technology (MUST) in Egypt, Future University in Egypt (FUE) and City of Scientific Research and Technological Applications (SERTA-City) in Egypt.
Academic Appointments: Adjunct Professor of Chemistry, College of Science and Technology (CST) at Temple University, Visiting Professor, Wolfson Centre for Age Related Diseases, School of Biomedical and Health Sciences, King's College London, Adjunct Professor of Medicinal Chemistry, Northeastern University, Center of Drug Discovery (CDD), Cairo University and the University of Ferrara, IT.